Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus

被引:83
|
作者
Henkel, E [1 ]
Menschikowski, M
Koehler, C
Leonhardt, W
Hanefeld, M
机构
[1] Tech Univ Dresden, Ctr Clin Studies Metab & Endocrinol, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Inst Klin Chem & Labormed, Fac Med CG Carus, D-01307 Dresden, Germany
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2005年 / 54卷 / 09期
关键词
D O I
10.1016/j.metabol.2005.03.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon is the physiological antagonist of insulin. Postprandial (pp) hyperglycemia in impaired glucose tolerance (IGT) and in type 2 diabetes mellitus (T2DM) may also depend on irregularities in glucagon secretion. This study investigated the glucagon excursion after a lip id-glucose-protein tolerance test in subjects with different stages of glucose intolerance. We also analyzed the relationship between pp glucagon secretion and hyperglycemias. A total of 64 men (27 healthy subjects with normal glucose tolerance [NGT], 15 with IGT, and 22 with T2DM) were examined. Plasma glucose (PG), insulin, proinsulin, free fatty acids, and triglycerides were measured in the fasting state and at 30 minutes and 2, 3, 4, and 6 hours after the intake of the test meal, which contained 126 g carbohydrates, 92 g fat, and 17 g protein. Postprandial concentrations of metabolic parameters were calculated as area under the curve (AUC). Glucagon was measured in the fasting state and at 30 minutes and 2 and 4 hours pp. Early glucagon increment was defined as glucagon at 30 minutes minus fasting glucagon. The insulin response was quantified as insulin increment divided by PG increment in the corresponding time. Insulin resistance was calculated using homeostasis model assessment (HOMA). Fasting glucagon was significantly increased in IGT vs NGT (P <.05), and early glucagon increment was significantly higher in T2DM vs NGT and IGT (P <.05). The 2-hour glucagon concentration after the load (AUC) was increased in IGT and T2DM vs NGT (P <.05). Early glucagon increment and the 2-hour AUC of glucagon were strongly correlated to pp glycemia (r = 0.494 and P =.001, and r = 0.439 and P =.003, respectively). An inverse correlation was observed between early glucagon increment and insulin response at 30 minutes and 2 hours after the meal load (r = -0.287 and P =.026, and r = -0.435 and P =.001, respectively). The 2-hour AUC of glucagon was significantly associated with insulin resistance (r = 0.354, P =.020). Multivariate analysis revealed 2-hour insulin response and early glucagon increment as significant independent determinants of the AUC of PG in IGT (R 0.787). In T2DM, 2-hour insulin response, insulin resistance, and early glucagon increment were significant determinants of the AUC of PG (R = 0.867). Our study suggests an important role for the irregularities in glucagon response in the pp glucose excursion after a standardized oral mixed meal in IGT and in T2DM. According to our data, a bihormonal imbalance starts before diabetes is diagnosed. Prospective studies are needed to evaluate the impact of glucagon on the progression of glucose intolerance and the possible effects of medicinal suppression of glucagon increment to prevent the progression of glucose tolerance. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1168 / 1173
页数:6
相关论文
共 50 条
  • [1] Postprandial triglyceridaemia in men with impaired fasting glucose, impaired glucose tolerance and diabetes
    Oka, R.
    Yagi, K.
    Hifumi, S.
    Miyamoto, S.
    Mabuchi, H.
    Yamagishi, M.
    Takeda, Y.
    Inazu, A.
    Nohara, A.
    Kawashiri, M.
    Kobayashi, J.
    [J]. DIABETIC MEDICINE, 2008, 25 (08) : 1008 - 1010
  • [2] Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus
    Guardado-Mendoza, Rodolfo
    Chavez, Alberto O.
    Jimenez-Ceja, Lilia M.
    Hansis-Diarte, Andrea
    DeFronzo, Ralph A.
    Folli, Franco
    Tripathy, Devjit
    [J]. ACTA DIABETOLOGICA, 2017, 54 (01) : 53 - 61
  • [3] Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus
    Rodolfo Guardado-Mendoza
    Alberto O. Chávez
    Lilia M. Jiménez-Ceja
    Andrea Hansis-Diarte
    Ralph A. DeFronzo
    Franco Folli
    Devjit Tripathy
    [J]. Acta Diabetologica, 2017, 54 : 53 - 61
  • [4] Postprandial lipaemia in patients with impaired fasting glucose, impaired glucose tolerance and diabetes mellitus
    Madhu, S. V.
    Kant, S.
    Srivastava, S.
    Kant, R.
    Sharma, S. B.
    Bhadoria, D. P.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 80 (03) : 380 - 385
  • [5] Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus
    Shah, P
    Vella, A
    Basu, A
    Basu, R
    Schwenk, WF
    Rizza, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11): : 4053 - 4059
  • [6] Treatment with acarbose reduces postprandial hyperglycemia in subjects with impaired glucose tolerance or early untreated type 2 diabetes
    Byrne, MM
    Burhorn, M
    Goeke, B
    [J]. DIABETES, 2000, 49 : A341 - A341
  • [8] The impact of redefining impaired fasting glucose in children at risk for impaired glucose tolerance and type 2 diabetes mellitus
    Hadjiyannakis, S
    Lawrence, SE
    Ward, LM
    Lawson, ML
    [J]. PEDIATRIC RESEARCH, 2004, 55 (04) : 144A - 144A
  • [9] Effect of postprandial hyperglycaemia on coronary flow reserve in patients with impaired glucose tolerance and type 2 diabetes mellitus
    Ikeda, Hiroyuki
    Uzui, Hiroyasu
    Morishita, Tetsuji
    Fukuoka, Yoshitomo
    Sato, Takehiko
    Ishida, Kentaro
    Kaseno, Kenichi
    Arakawa, Kenichiro
    Amaya, Naoki
    Tama, Naoto
    Shiomi, Yuichiro
    Lee, Jong-Dae
    Tada, Hiroshi
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (06): : 405 - 410
  • [10] Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus
    Guerrero-Romero, F.
    Rodriguez-Moran, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (11) : 796 - 802